An observational study in Diabetic Macular Edema, Neovascular Age-related Macular Degeneration and Retinal Vein Occlusion, sponsored by Hoffmann-La Roche. Active, not recruiting at 41 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Hoffmann-La Roche · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Retinal Vein Occlusion with a site in China — 8 open to participants now, 12 under way, 1 of them phase 3. Retinal Vein Occlusion · China.
Among the 37 studies in Retinal Vein Occlusion with a site in China, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2024, is one of 11 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 26th registered.
291 studies on the registry are indexed under Retinal Vein Occlusion; 33 are open to participants now.
Browse Retinal Vein Occlusion studies →8 of the 37 studies in Retinal Vein Occlusion with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–80
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 50+
Renmin Hospital of Wuhan University · Sites in China
Ages 18+
Renmin Hospital of Wuhan University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 19 Retinal Vein Occlusion studies recruiting now, 14 (74%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 11 · Phase 4 3
First in 2011; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 180 across 71 observational studies indexed under Retinal Vein Occlusion.
Median enrollment 135 across the 26 interventional studies, 1,000 across the 11 observational. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 37 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 7 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
2 of the studies in Retinal Vein Occlusion with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07201415Zhongnan HospitalMinimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma | 2026-12-31 |
| NCT07133438First Affiliated Hospital of Chongqing Medical UniversityMecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Retinal Vein Occlusion with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China. It is a primary data collection, non-interventional, prospective and retrospective, multi-center study designed to collect real-world, long-term data to gain clinical evidence on faricimab, by observing cohorts of patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) who are receiving treatment with faricimab.
The study will recruit patients who are naïve to anti-VEGF therapy in the study eye and those who have previously been treated with anti-VEGF therapy in the study eye. Study participation of patients previously treated with other anti-VEGF agents will be capped at a maximum of 40% of each indication enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faricimab
Drug: Faricimab
Drug: Faricimab
The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
Also known as: VABYSMO®
Change in Visual Acuity from Baseline at Month 12
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Time frame: Baseline and Month 12
Visual Acuity Over Time
Time frame: Baseline, Months 3, 6, 9, 12, 18, and 24
Change in Visual Acuity from Baseline Over Time
Time frame: Baseline, Months 3, 6, 9, 18, and 24
Central Subfield Thickness Over Time
Time frame: Baseline, Months 3, 6, 9, 12, 18, and 24
Change in Central Subfield Thickness from Baseline Over Time
Time frame: Baseline, Months 3, 6, 9, 12, 18, and 24
Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other)
Time frame: From Baseline to Month 24
Number of Treatments per Year
Time frame: Months 12 and 24
Percentage of Eyes with Treatment Switch by Reason for Switch Over Time
Time frame: Months 3, 6, 9, 12, 18, and 24
Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Over Time
Time frame: Months 3, 6, 9, 12, 18, and 24
Total Number of Visits per Year
Time frame: Months 12 and 24
Number of Visits With or Without Treatment per Year
Time frame: Months 12 and 24
Time Interval Between Treatments per Year
Time frame: Months 12 and 24
Percentage of Eyes Treated with Ocular Concomitant Medications or Therapy by Type and Frequency During the Study
Time frame: From Baseline until end of study (up to 3.5 years)
Number of Participants Lost to Follow-Up More Than 6 Months at Months 12, 18, and 24
Time frame: Months 12, 18, and 24
Percentage of Eyes According to the Last Treatment Interval at Months 3, 6, 12, 18, and 24
Time frame: Months 3, 6, 12, 18, and 24
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Oct 2026, 29 months.
Of 26 observational studies under Retinal Vein Occlusion, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 69. This study's 29 months is below that.
Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.